Terms: = Bone cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Diagnosis
87 results:
1. Pediatric neuroblastoma with intraspinal extension: the role of surgical management.
Chang D; Oh T; Roland JL; Matthay KK; Vo KT; Edwards CS; Sun PP; Auguste KI; Gupta N
J Neurosurg Pediatr; 2024 Mar; 33(3):245-255. PubMed ID: 38100763
[TBL] [Abstract] [Full Text] [Related]
2. Stage 4N neuroblastoma before and during the era of anti-G
Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
[TBL] [Abstract] [Full Text] [Related]
3. Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.
Wieczorek A; Stefanowicz J; Hennig M; Adamkiewicz-Drozynska E; Stypinska M; Dembowska-Baginska B; Gamrot Z; Woszczyk M; Geisler J; Szczepanski T; Skoczen S; Ussowicz M; Pogorzala M; Janczar S; Balwierz W
BMC Cancer; 2022 Jun; 22(1):701. PubMed ID: 35752779
[TBL] [Abstract] [Full Text] [Related]
4. Pediatric Extraspinal Subcutaneous Sacrococcygeal Myxopapillary Ependymoma: Case Report and Minireview.
Liu Y; Peng Y; Wang X; Guo Z; Xiang C; Wan W; Wang X; Hu Y
Am J Dermatopathol; 2021 Dec; 43(12):e273-e276. PubMed ID: 34797808
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Poetsch AR; Jaschke N; Hofbauer LC; Göbel A; Rachner TD; Kuhlmann JD
Clin Chem Lab Med; 2022 Jan; 60(1):109-117. PubMed ID: 34687595
[TBL] [Abstract] [Full Text] [Related]
6. The Significance of Histopathologic Assessment in bone Marrow Disease in Neuroblastoma.
Ekmekci S; Ince D; Olgun N; Ozer E
Turk Patoloji Derg; 2022; 38(2):99-105. PubMed ID: 34558657
[TBL] [Abstract] [Full Text] [Related]
7. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract] [Full Text] [Related]
8. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
[TBL] [Abstract] [Full Text] [Related]
9. GAS7 Deficiency Promotes Metastasis in mycn-Driven Neuroblastoma.
Dong Z; Yeo KS; Lopez G; Zhang C; Dankert Eggum EN; Rokita JL; Ung CY; Levee TM; Her ZP; Howe CJ; Hou X; van Ree JH; Li S; He S; Tao T; Fritchie K; Torres-Mora J; Lehman JS; Meves A; Razidlo GL; Rathi KS; Weroha SJ; Look AT; van Deursen JM; Li H; Westendorf JJ; Maris JM; Zhu S
Cancer Res; 2021 Jun; 81(11):2995-3007. PubMed ID: 33602789
[TBL] [Abstract] [Full Text] [Related]
10. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
Moreno L; Guo D; Irwin MS; Berthold F; Hogarty M; Kamijo T; Morgenstern D; Pasqualini C; Ash S; Potschger U; Ladenstein R; Valteau-Couanet D; Cohn SL; Pearson ADJ; London WB
Pediatr Blood Cancer; 2021 Mar; 68(3):e28794. PubMed ID: 33205902
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
12. mycn amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive evaluation of context dependence of the prognostic impact of mycn amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract] [Full Text] [Related]
14. Neuroblastoma of the bone and bone Marrow Without an Apparent Primary Site: Report of 4 Cases With Long-term Follow-up.
Rainusso N; Seghers V; Egler R; Hicks J; Russell HV
Pediatr Dev Pathol; 2019; 22(4):329-333. PubMed ID: 30600764
[TBL] [Abstract] [Full Text] [Related]
15. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract] [Full Text] [Related]
16. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.
Corrias MV; Parodi S; Tchirkov A; Lammens T; Vicha A; Pasqualini C; Träger C; Yáñez Y; Dallorso S; Varesio L; Luksch R; Laureys G; Valteau-Couanet D; Canete A; Pöetschger U; Ladenstein R; Burchill SA
Pediatr Blood Cancer; 2018 Jul; 65(7):e27052. PubMed ID: 29603574
[TBL] [Abstract] [Full Text] [Related]
17. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract] [Full Text] [Related]
18. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract] [Full Text] [Related]
19. Management of Neuroblastoma: ICMR Consensus Document.
Bansal D; Totadri S; Chinnaswamy G; Agarwala S; Vora T; Arora B; Prasad M; Kapoor G; Radhakrishnan V; Laskar S; Kaur T; Rath GK; Bakhshi S
Indian J Pediatr; 2017 Jun; 84(6):446-455. PubMed ID: 28367616
[TBL] [Abstract] [Full Text] [Related]
20. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract] [Full Text] [Related]
[Next]
